Wherever possible the use of licensed medicines is encouraged to assure safety and efficacy. For many common dermatological
|
diseases including psoriasis and eczema, the range of licensed medicines is limited. As a result, Dermatology prescribing may
|
rely significantly on unlicensed creams and ointments (known as ‘Specials’) containing tars, dithranol, salicylic acid, steroids and
|
other active constituents in a range of concentrations and bases. This is of particular concern in primary care where lack of
|
effective price controls and a mechanism to ensure independent scrutiny of product quality has increased costs and concern about
|
standards. To address these concerns and help to optimise quality of care Dermatology 'Specials' should only be prescribed from the document:
|
| 'Specials Recommended by the British Association of Dermatologists for Skin Disease' |
| |
The prescribing of such products may be continued in Primary Care. When a product is required that is not included in the 'BAD'
|
list then the prescribing of such will remain with the Consultant/Prescriber and may not be continued in Primary Care. Where a
|
preparation is required that is not listed in the BAD document then there is a requirement to submit a request to East Lancashire
|
Medicines Management Board (ELMMB) for the product to be considered for inclusion in the formulary.
|
| |
